<DOC>
	<DOCNO>NCT00856310</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled single-dose study safety tolerability intravenously administer REGN475 healthy volunteer . The primary objective study assess safety tolerability REGN475 . The secondary objective characterize pharmacokinetic immunogenicity profile REGN475 .</brief_summary>
	<brief_title>A Single-Dose Study Safety Tolerability REGN475 ( SAR164877 ) Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Key Male female volunteer , general good health 21 65 year age . Female volunteer must postmenopausal least 1 year surgically sterile . Key Significant concomitant illness , limited , cardiac , renal , neurological , endocrinological , GI , hepatic , metabolic lymphatic disease would adversely affect subject 's participation study interpretation safety/ PK data Participation clinical research study evaluate another investigational drug therapy within 3 week least 5 halflives investigational drug , whichever longer , prior Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Healthy volunteer</keyword>
</DOC>